University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Douglas Goodin, M.D.

Director of the Multiple Sclerosis Center

Dr. Douglas Goodin, director of the Multiple Sclerosis Center at UCSF Medical Center, is a neurologist and an internationally renowned expert in the treatment and research of multiple sclerosis.. He earned a bachelor of sciences degree in genetics and biochemistry at the University of Washington in Seattle; a master of sciences degree in molecular biology at Purdue University in Indiana; and a medical degree from the University of California, Irvine. He completed a residency in neurology at UCSF where he joined the medical center staff in 1982. In addition to multiple sclerosis, Goodin's research interests include various forms of dementia. Goodin also is a professor of neurology at UCSF.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

More about Douglas Goodin

Education

University of California, Irvine 1978

Residencies

UCSF, Neurology 1982

Selected Research and Publications

  1. Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D. Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS One. 2014; 9(8):e105207.
  2. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von BŘdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Aug 1.
  3. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C. Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014 Sep 15; 344(1-2):80-7.
  4. Goodin DS, Khankhanian P. Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations. PLoS One. 2014; 9(4):e90034.
  5. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
  6. Goodin DS. Preface. Handb Clin Neurol. 2014; 122:ix-x.
  7. Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014; 122:231-66.
  8. Goodin DS. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014; 122:455-64.
  9. Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C. Interleukin 17F level and interferon ▀ response in patients with multiple sclerosis. JAMA Neurol. 2013 Aug; 70(8):1017-21.
  10. Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. Neurology. 2013 Jul 9; 81(2):184-92.
  11. Goodin DS. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin Neurol. 2013 Feb; 33(1):13-25.
  12. Goodin DS. The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. PLoS One. 2012; 7(12):e47875.
  13. Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFN▀-1b study. BMJ Open. 2012; 2(6).
  14. Goodin DS, Reder AT. Response to GS Gronseth and E Ashman. Mult Scler. 2012 Nov; 18(11):1661-2; author reply 1663-4.
  15. Goodin DS, Reder AT, Cutter G. Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8.
  16. Goodin DS, Reder AT. Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
  17. Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J. Variability in detection and quantification of interferon ▀-1b-induced neutralizing antibodies. J Neuroinflammation. 2012; 9:129.
  18. Marcus JF, Goodin DS, Harris CA, Josephson SA. Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply. Arch Neurol. 2012 Jun 1; 69(6):793-4.
  19. Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One. 2012; 7(5):e36847.
  20. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN▀-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.